NUTEX HEALTH RESPONDS TO SHORT SELLER REPORT

Rhea-AI Summary

{"summary":"","positive":[],"negative":[],"faq":[]}

News Market Reaction

-5.38%

15 alerts

-5.38% News Effect

+5.9% Peak Tracked

-2.8% Trough Tracked

-$46M Valuation Impact

$802M Market Cap

1.2x Rel. Volume

On the day this news was published, NUTX declined 5.38%, reflecting a notable negative market reaction. Argus tracked a peak move of +5.9% during that session. Argus tracked a trough of -2.8% from its starting point during tracking. Our momentum scanner triggered 15 alerts that day, indicating notable trading interest and price volatility. This price movement removed approximately $46M from the company's valuation, bringing the market cap to $802M at that time.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Short report date: November 25, 2025 10-Q reference: Part II Item 1 Related party note: Note 17 +1 more

4 metrics

Short report date November 25, 2025 Date Capybara Research report was issued

10-Q reference Part II Item 1 Section describing legal proceedings in Q3 2025 10-Q

Related party note Note 17 Condensed Consolidated Financial Statements disclosure

10-K amendment date April 30, 2025 Date of Amendment No. 1 to Form 10-K

Market Reality Check

Price: $149.80 Vol: Volume 148,751 is below t...

low vol

$149.80 Last Close

Volume Volume 148,751 is below the 20-day average 219,785 with relative volume at 0.68x. low

Technical Price 190.49 is trading above the 200-day MA at 107.84, near the 52-week high 187.2.

Peers on Argus

Peers showed mixed moves: AGL up 8.72%, INNV up 4.48%, while EHAB and SNDA were ...

Peers showed mixed moves: AGL up 8.72%, INNV up 4.48%, while EHAB and SNDA were down modestly. This contrasts with NUTX’s company-specific short-seller related headline.

Historical Context

5 past events · Latest: Dec 04 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Dec 04	Share repurchase	Positive	+19.0%	Extended <b>$25.0M</b> stock buyback through <b>March 31, 2026</b>.
Nov 26	Short report response	Negative	-5.4%	Company rebutted anonymous short-seller report and referenced existing disclosures.
Nov 24	Facility reopening	Positive	+0.2%	Reopened Red River ER & Hospital with upgraded 24/7 capabilities.
Nov 19	Q3 2025 earnings	Positive	+13.1%	Reported strong Q3 and nine‑month 2025 revenue and profitability growth.
Nov 18	Q2 2025 earnings	Positive	-4.6%	Strong H1 2025 revenue and cash, but heavy stock-based compensation.

Pattern Detected

Recent fundamental and capital allocation news, including strong earnings and a $25.0M buyback, mostly saw positive price alignment, with only one earnings event showing divergence.

Recent Company History

This announcement follows a series of material developments for Nutex Health. In mid-November, amended 10-Q and 10-K/A filings restated financials and highlighted internal control weaknesses. Earnings for Q2 and Q3 2025 showed sharply higher revenue, net income, and cash, with notable non-cash stock-based compensation and arbitration-related items. The stock reacted positively to Q3 results and the extension of a $25.0M repurchase program, while an earlier strong earnings release drew a negative reaction. The short-seller response sits against this backdrop of rapid growth and recent restatements.

Market Pulse Summary

The stock moved -5.4% in the session following this news. A negative reaction despite the company’s ...

Analysis

The stock moved -5.4% in the session following this news. A negative reaction despite the company’s rebuttal fits a backdrop of heightened scrutiny. Nutex Health recently restated financials via amended 10-Q/A and 10-K/A filings and disclosed unresolved material weaknesses in internal controls, alongside heavy non-cash stock-based compensation. Even with strong reported revenue and net income growth in 2025, investors may have focused on governance and reporting risks, making shares more sensitive to any short-seller allegations and related uncertainty.

Key Terms

short seller, 10-q, form 10-k, related party transactions, +1 more

5 terms

short seller financial

"Nutex Health Inc. ... is aware of a short seller report issued on November 25, 2025"

An investor who bets a stock will fall by borrowing shares and selling them now, then later buying them back to return to the lender; profit comes if the repurchase price is lower than the sale price. Like borrowing a book to sell and hoping to buy it back cheaper later, short sellers can pressure prices, reveal problems, and increase volatility, so their activity can signal risk or create trading opportunities for other investors.

10-q regulatory

"Legal Proceedings of the Company's 10-Q for the period ended September 30, 2025"

A 10-Q is a company’s required quarterly filing with U.S. regulators that provides updated financial statements, management discussion of results, and disclosures about risks, legal matters and operational changes. Think of it as a quarterly report card and progress update that lets investors track recent performance, spot trends or warning signs between annual reports, and make informed buy/sell decisions based on the latest verified financial and business information.

form 10-k regulatory

"Amendment No. 1 to our Form 10-K filed on April 30, 2025"

A Form 10-K is a comprehensive report that publicly traded companies are required to file annually with regulators. It provides a detailed overview of a company's financial health, operations, and risks, similar to a detailed health report. Investors use this information to assess the company's performance and make informed decisions about buying or selling its stock.

related party transactions financial

"its related party transactions and policies are described in Note 17"

Transactions between a company and people or entities that have close ties to it—such as executives, board members, major shareholders, family members, or related companies—where the parties are not independent. These deals matter to investors because they can create conflicts of interest or hide favorable terms that distort a company’s true profits and risks; think of it like a business buying or selling to a family member instead of using the open market, which can lead to biased prices or undisclosed obligations.

director independence regulatory

"Item 13. Certain Relationships and Related Persons Transactions, and Director Independence"

Director independence describes board members who have no significant personal, financial or business ties to the company that could bias their judgment, acting more like neutral referees than interested parties. Investors care because independent directors help ensure management is held accountable, reduce the risk of self-dealing or friendly decisions, and increase confidence that board choices are aimed at long-term shareholder value rather than private interests.

AI-generated analysis. Not financial advice.

HOUSTON, Nov. 26, 2025 /PRNewswire/ -- Nutex Health Inc. ("Nutex Health" or the "Company") (NASDAQ: NUTX), is aware of a short seller report issued on November 25, 2025 by Capybara Research. Based on publicly available information, Capybara Research as an entity seems not to exist.  In the past, lawsuits filed against Capybara by other victims of its abusive tactics could not be served because the person or persons controlling Capybara have taken actions to conceal their identity and location.

The sole purpose of this attack appears to be to create market confusion and to profit from the decline in trading price caused as a result.  Unfortunately, this has become a common short seller tactic that many public companies have encountered.

The allegations in the report appear to be insinuations based on either outdated, inapplicable, incomplete or wrong factual information. 

The Company's material legal proceedings and disputes are described in Part II Item 1--Legal Proceedings of the Company's 10-Q for the period ended September 30, 2025 filed on November 19, 2025 ("Third Quarter 10-Q"), and its related party transactions and policies are described in Note 17 to the Company's Condensed Consolidated Financial Statements contained in the Third Quarter 10-Q and in Amendment No. 1 to our Form 10-K filed on April 30, 2025 in Part III, Item 13. Certain Relationships and Related Persons Transactions, and Director Independence.

The Company does not intend to comment further on this short seller report.

About Nutex Health Inc.

Headquartered in Houston, Texas and founded in 2011, Nutex Health Inc. (NASDAQ: NUTX) is a healthcare management and operations company with two divisions: a Hospital Division and a Population Health Management Division.

The Hospital Division owns, develops and operates innovative health care models, including micro-hospitals, specialty hospitals, and hospital outpatient departments (HOPDs). This division owns and operates 24 facilities in 11 states.

The Population Health Management division owns and operates provider networks such as Independent Physician Associations (IPAs). Through our Management Services Organization (MSO), we provide management, administrative and other support services to our affiliated hospitals and physician groups.

Forward-Looking Statements

Certain statements and information included in this press release constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the Company's future expectations, beliefs, plans, objectives, financial condition, assumptions or future events or performance that are not historical facts.

When used in this press release, the words or phrases "will", "will likely result," "expected to," "will continue," "anticipated," "estimate," "projected," "intend," "goal," or similar expressions are intended to identify "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are subject to certain risks, known and unknown, and uncertainties, many of which are beyond the control of the Company. In addition to the items listed above, such uncertainties and risks include, but are not limited to, our ability to successfully execute our growth strategy, to finalize the required amendments to and delinquent SEC filings in the anticipated time frame, to remediate the additional weakness in a timely manner, changes in laws or regulations, including the interim final and final rules implemented under the No Surprises Act and the federal arbitration process, economic conditions, dependence on management, dilution to stockholders, lack of capital, the effects of rapid growth upon the Company and the ability of management to effectively respond to the growth and demand for products and services of the Company, newly developing technologies, the Company's ability to compete, conflicts of interest in related party transactions, regulatory matters, protection of technology, lack of industry standards, the effects of competition and the ability of the Company to obtain future financing. An extensive list of factors that can affect future results are discussed in our Quarterly Report on Form 10-Q for the period ended September 30, 2025 filed with the SEC on November 19, 2025, our Annual Report on Form 10-K for the year ended December 31, 2024, and the risk factors and other cautionary statements contained in other documents filed from time to time with the Securities and Exchange Commission. Such factors could materially adversely affect the Company's financial performance and could cause the Company's actual results for future periods to differ materially from any opinions or statements expressed within this press release.

View original content:https://www.prnewswire.com/news-releases/nutex-health-responds-to-short-seller-report-302627113.html

SOURCE Nutex Health, Inc.